The pharmacological blockade of type 2 inflammation by therapeutic antibodies against IgE, IL-5, or IL-5/IL-4/-13 receptors, so far has not been suspected to increase the risk of viral infections, also in the respective approving clinical trials (Klimek et al., 2020). Here, IL5 is linked to viral infectious disease.